Tenapanor manufacturers
- Tenapanor
-
- $31.00
-
2026-07-17
- CAS:1234423-95-0
- Purity: 99.85%
- Supply Ability: 10g
- Tenapanor
-
-
2026-06-30
- CAS:1234423-95-0
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kg
- Tenapanor
-
-
2024-10-31
- CAS:1234423-95-0
- Min. Order: 10g
- Purity: 0.99
- Supply Ability: 1KG
|
| | Tenapanor Basic information |
| Product Name: | Tenapanor | | Synonyms: | Tenapanor;Rovatirelin Hydrate;Tenapanor(free base);AZD-1722; AZD 1722; AZD1722; RDX 5791; RDX-5791; RDX5791; TENAPANOR FREE BASE; IBSRELA.;Ibsrela.;Tenapanor (AZD1722，RDX5791);CS-2459;AZD1722 | | CAS: | 1234423-95-0 | | MF: | C50H66Cl4N8O10S2 | | MW: | 1145.04 | | EINECS: | | | Product Categories: | | | Mol File: | 1234423-95-0.mol |  |
| | Tenapanor Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (43.67 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | color | White to off-white | | InChIKey | DNHPDWGIXIMXSA-KQPQOZEFNA-N | | SMILES | ClC1C=C(Cl)C=C2[C@H](C3C=CC=C(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(C4C=CC=C([C@@H]5CN(C)CC6=C(C=C(Cl)C=C56)Cl)C=4)(=O)=O)C=3)CN(C)CC=12 |&1:7,52,r| |
| | Tenapanor Usage And Synthesis |
| Uses | Tenapanor is a medicine. This drug targets Nsp16 protein may corroborates a promising approach to combat SARS-CoV-2 virus. | | in vivo | Tenapanor (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats[1].
Tenapanor (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats[2]. | Animal Model: | Rats (intestinal loop model)[1] | | Dosage: | 0.15, 0.5 mg/kg | | Administration: | P.o. | | Result: | Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum. |
| Animal Model: | 8 weeks, 250 g male Sprague–Dawley rats[2] | | Dosage: | 0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt)) | | Administration: | Oral gavage; twice-daily for 11 consecutive days | | Result: | Significantly augmented the reduction in urinary phosphorus excretion. |
|
| | Tenapanor Preparation Products And Raw materials |
|